Archives for September 2011

Vismodegib for Basal Cell Carcinoma

Vismodegib is an inhibitor of the hedgehog signaling pathway, a pathway involved in regulating adult stem cells that is over-active in more than 90% of basal cell carcinomas. This phase II clinical trial resulted in an increased progression free… [Learn More…]

Amazing Results From ICT-107 Glioblastoma Clinical Trial

ICT-107 is a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma and is showing an 80.2% overall survival at 2yrs and 55% overall survival at 3yrs, with 38% of patients disease free at 3yrs…compared to a… [Learn More…]

DCVax: Slowing the Progression of Metastatic Prostate Cancer.

Prostate cancer patients whom experience rising PSA levels while on hormone treatment typically progress to metastatic disease on average in about 28-36 weeks. DCVax is a vaccine made from a patient’s own dendritic cells and loaded with a form of… [Learn More…]

JX-594: A Targeted Oncolytic Poxvirus, Followed by Sorafenib in Hepatocellular Carcinoma

JX-594 is a targeted and granulocyte-macrophage colony stimulating factor (GM-CSF) expressing oncolytic poxvirus designed to selectively replicate in and destroy cancer cells through viral oncolysis and tumor-specific immunity. In this trial,… [Learn More…]